The Cooper Companies, Inc. COO

Health CareHealthcare Equipment & SuppliesUnited States of America

Last close 60.83 USD on Nov 3, 2026, −25.8% year to date

Quant rating

Quant rating C Rank 241 of 565 in Health Care

Growth C 271 of 565
Valuation A 39 of 565
Quality B 124 of 565
Revisions D 401 of 565
Momentum D 396 of 565

Wall Street consensus Hold (2.61)Average target 69.07 USD +13.5%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 11.6B
Enterprise value: 14.0B
52-week range: 51.01 – 89.66
3-year range: 51.01 – 111.23
Dividend yield: –
Beta (5 years): 0.81
Shares outstanding: 190M
Next earnings: Dec 2, 2026

About the company

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.

Growth and profitability fiscal year ends October 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	4,092	3,895	3,593	3,308	2,922	–
Revenue growth	5.1%	8.4%	8.6%	13.2%	20.2%	11.0%
EPS (basic, normalized)	4.12	3.69	3.20	3.10	3.31	–
EPS growth	11.7%	15.2%	3.1%	−6.2%	–	–
Gross margin	65.5%	66.6%	65.6%	65.5%	66.9%	66.0%
Net margin	9.2%	10.1%	8.2%	11.7%	100.8%	28.0%
ROE	4.6%	5.0%	4.0%	5.5%	54.7%	14.8%

Balance sheet, last quarter
Cash & short-term investments (mil)	155
Current ratio	1.22x
Long-term debt (mil)	1,916
Net debt (mil)	2,390
Total equity (mil)	8,328
Net debt / equity	0.29x
Net debt / EBITDA	1.94x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	4,092	+5.1%	3.4x	1,234	+7.4%	11.3x	4.12	+11.7%	14.8x
2026	4,239	+3.6%	3.3x	1,321	+7.0%	10.6x	4.53	+9.9%	13.4x
2027	4,412	+4.1%	3.2x	1,376	+4.2%	10.1x	4.69	+3.6%	13.0x
2028	4,621	+4.7%	3.0x	1,466	+6.6%	9.5x	5.10	+8.6%	11.9x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	4,239	0.0%	−1.6%	−1.9%	4.53	+0.1%	−2.1%	−1.9%
2027	4,412	0.0%	−2.4%	−3.0%	4.69	0.0%	−6.1%	−6.7%
2028	4,621	0.0%	−2.8%	−3.6%	5.10	+0.1%	−6.0%	−7.0%

Earnings surprises EPS beat in 4 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Apr 2024	Jul 2024	Oct 2024	Jan 2025	Apr 2025	Jul 2025	Oct 2025	Jan 2026	Apr 2026	Jul 2026
Sales reported (mil)	943	1,003	1,018	965	1,002	1,060	1,065	1,024	1,082	1,066
Sales mean (mil)	948	997	1,027	978	995	1,064	1,060	1,026	1,054	1,098
Surprise	−0.6%	+0.6%	−0.8%	−1.4%	+0.7%	−0.3%	+0.4%	−0.2%	+2.6%	−2.9%
EPS reported	0.85	0.96	1.04	0.92	0.96	1.10	1.15	1.10	1.21	1.15
EPS mean	0.83	0.91	1.00	0.91	0.93	1.07	1.11	1.03	1.10	1.12
Surprise	+2.6%	+5.5%	+4.1%	+0.8%	+3.5%	+2.9%	+3.3%	+6.8%	+10.4%	+2.8%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
COO The Cooper Companies, Inc.	11.6B	1.94x	9.2%	1.39x	13.4x	13.0x	10.6x	10.1x
ABT Abbott Laboratories	189.3B	2.36x	14.7%	3.70x	19.8x	18.4x	16.4x	14.9x
ISRG Intuitive Surgical, Inc.	152.8B	−0.91x	28.4%	9.56x	39.2x	35.3x	26.7x	24.5x
MDT Medtronic PLC	126.5B	1.99x	13.2%	2.52x	16.5x	15.5x	13.1x	12.6x
SYK Stryker Corporation	118.2B	1.65x	12.9%	5.04x	20.9x	19.0x	16.6x	15.5x
BSX Boston Scientific Corporation	63.1B	1.90x	14.4%	2.46x	13.7x	13.9x	11.8x	11.8x
Mean		1.49x	15.5%	4.11x	20.6x	19.2x	15.9x	14.9x
Median		1.92x	13.8%	3.11x	18.2x	17.0x	14.8x	13.7x

Technical analysis

1M+6.9%
3M−18.1%
1Y−12.9%
3Y−27.3%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, The Cooper Companies, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	4,092	3,895	3,593	3,308	2,922	2,431
Cost of revenue	1,410	1,300	1,235	1,142	967	896
Gross profit	2,682	2,596	2,358	2,166	1,956	1,535
Selling, general & administrative expenses	1,628	1,534	1,456	1,346	1,134	966
Research & development	172	155	137	110	92.7	93.3
Depreciation/amortization	199	201	186	180	146	137
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	–	–	45.0	33.2	10.9	26.3
Other operating expenses	0	0	0	−10.3	66.1	0
Operating income	683	706	533	508	506	312
Net interest income (expense)	−108	−120	−112	−31.6	−17.0	−38.0
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	−8.4	−3.9	−7.9	−0.7	2.7	−7.3
Net income before taxes	566	582	413	475	492	266
Provision for taxes	192	190	119	89.5	−2,453	28.1
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	375	392	294	386	2,945	238
Extraordinary items	–	–	–	–	–	0
Net income	375	392	294	386	2,945	238
EBIT, normalized	683	706	578	541	517	338
EBITDA, normalized	1,060	1,081	946	887	826	625
Basic EPS, normalized	4.12	3.69	3.20	3.10	3.31	–

Balance sheet in millions of USD, fiscal years

Balance sheet, The Cooper Companies, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	111	108	121	138	95.9	116
Receivables	829	717	610	558	515	435
Total inventory	846	803	736	629	586	570
Prepaid expenses	321	324	239	209	179	152
Other current assets	0	0.1	0.1	0	89.2	0
Total current assets	2,106	1,952	1,705	1,534	1,465	1,274
Property, plant & equipment	2,353	2,124	1,874	1,663	1,605	1,542
Goodwill	3,853	3,838	3,624	3,610	2,574	2,447
Intangibles	1,586	1,791	1,710	1,885	1,272	1,289
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	2,496	2,610	2,745	2,801	2,691	185
Total assets	12,395	12,315	11,659	11,492	9,606	6,738
Liabilities
Accounts payable	300	260	262	249	161	176
Payable/accrued	–	–	–	–	–	–
Accrued expenses	248	213	213	188	184	152
Short-term debt	47.1	32.2	44.4	396	82.9	59.4
Current portion of long-term debt	0.7	1.1	1.0	16.9	0	350
Other current liabilities	516	516	449	431	303	267
Total current liabilities	1,113	1,023	969	1,280	732	1,004
Long-term debt	2,458	2,550	2,524	2,351	1,396	1,384
Minority interest	0.2	0.2	0.2	0.2	0.2	0.2
Other liabilities	585	658	615	687	536	524
Total liabilities	4,156	4,232	4,108	4,318	2,664	2,913
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	21.8	21.7	5.4	5.4	5.4	5.3
Additional paid-in capital	1,976	1,921	1,833	1,766	1,715	1,647
Retained earnings (accumulated deficit)	7,643	7,268	6,876	6,585	6,202	3,262
Treasury stock	−995	−706	−710	−714	−640	−617
Other equity	−406	−422	−454	−467	−341	−472
Total equity	8,239	8,083	7,551	7,174	6,942	3,825
Total liabilities & shareholders' equity	12,395	12,315	11,659	11,492	9,606	6,738

Cash flow statement in millions of USD, fiscal years

Cash flow statement, The Cooper Companies, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	375	392	294	386	2,945	238
Depreciation, depletion & amortization	377	375	368	346	309	287
Deferred taxes	135	119	44.7	53.9	−2,502	−0.9
Non-cash items	193	157	120	80.6	137	87.8
Changes in working capital	−285	−334	−219	−174	−150	−126
Cash from operations	796	709	608	692	739	487
Investing activities
Capital expenditures	−362	−421	−392	−242	−214	−310
Other investing cash flows	−10.5	−343	−56.5	−1,589	−236	−54.1
Cash from investing	−373	−765	−449	−1,831	−450	−364
Financing activities
Financing cash flow items	−66.5	25.3	2.0	−10.8	20.4	−10.3
Cash dividends paid	0	0	−3.0	−3.0	−3.0	−3.0
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−359	13.9	−173	1,208	−329	−82.2
Cash from financing	−426	39.2	−174	1,194	−311	−95.5
Foreign exchange effects	5.6	2.9	−2.3	−12.9	2.9	0.7
Net change in cash	2.9	−13.2	−17.7	42.0	−20.2	27.3
Free cash flow	434	288	215	450	524	176

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 3, 2026 after market close.